Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant
This is a single-patient extended access treatment protocol to be conducted in the United States. Investigator-Physician has determined patient satisfies expanded access inclusion criteria and has requested expanded access to tradipitant. Patient will be given open label tradipitant 85 mg to be taken twice daily at 12 hour intervals for long term treatment. Patient can fill out daily web-based symptom diaries on a voluntary basis and report any adverse events to Investigator-Physician. Primary Objective: -To treat a single patient with gastroparesis who has requested expanded access with tradipitant Secondary Objectives: * To monitor the efficacy of tradipitant in reducing individual symptoms associated with gastroparesis in this single patient * To monitor the safety of tradipitant in a patient with gastroparesis by assessing adverse events in this single patient
Study Type
EXPANDED_ACCESS
NK-1 Receptor antagonist
Vanda Investigational Site
Maitland, Florida, United States
AVAILABLEVanda Investigational Site
Tampa, Florida, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vanda Investigational Site
Wauconda, Illinois, United States
AVAILABLEVanda Investigational Site
Wichita, Kansas, United States
AVAILABLEVanda Investigational Site
Louisville, Kentucky, United States
AVAILABLEVanda Investigational Site
Chevy Chase, Maryland, United States
AVAILABLEVanda Investigational Site
Boston, Massachusetts, United States
AVAILABLEVanda Investigational Site
Chesterfield, Missouri, United States
AVAILABLEVanda Investigational Site
Charlotte, North Carolina, United States
AVAILABLEVanda Investigational Site
Tulsa, Oklahoma, United States
AVAILABLE...and 5 more locations